KATIOFSKY1 in 1939 reported his experience with a new sulfonamide, sodium sulfacetamide, in the treatment of diseases of the eye. His article initiated a series of studies of the drug in the management of trachoma, ophthalmia neonatorum, and other morbid conditions of the ocular tissues. The early reports all appeared in the German literature, but in 1941 Robson and Scott2 in England used the drug in the local treatment of experimental pyocyaneus ulcers of the cornea, and later Robson and Tebrich3 reported on the penetration of the drug into the eyes of rabbits. The first mention of the drug in the American literature was by Strakosch and Clark4 in 1943 in a comparative study on the penetration of sulfonamides into the skin. Sodium sulfacetamide, or Sodium Sulamyd5 (Schering),* is the monohydrated sodium salt of N-sulfanilylacetamide. It is highly soluble at the physiologic pH
DUEMLING WW. SODIUM SULFACETAMIDE IN TOPICAL THERAPY. AMA Arch Derm Syphilol. 1954;69(1):75–82. doi:10.1001/archderm.1954.01540130077007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: